Study Title
Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Study Details
Description:
A multicenter Phase II, randomized, prospective, open-label Trial investigating the clinical impact on combining Specific Internal Radiotherapy (SIRT) with the PD1-L Inhibitor Durvalumab and the CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contacts:
Arndt Vogel, Professorvogel.arndt@mh-hannover.de
+49 511 5326 ext 760
Doerthe Vortmeyer, Doctorvortmeyer.doerthe@ikf-khnw.de
+49 069 7601 ext 4196
Government Study Link:
NCT04238637 - Click here to see study onClinicalTrials.gov